U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H28N2O
Molecular Weight 336.4713
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENTANYL

SMILES

CCC(=O)N(c1ccccc1)C2CCN(CCc3ccccc3)CC2

InChI

InChIKey=PJMPHNIQZUBGLI-UHFFFAOYSA-N
InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3

HIDE SMILES / InChI

Molecular Formula C22H28N2O
Molecular Weight 336.4713
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.addictioncenter.com/painkillers/fentanyl/ | https://www.ncbi.nlm.nih.gov/pubmed/24635521

Fentanyl is a potent agonist of mu opioid receptor. It is used to relieve severe pain, such as after surgery or during cancer treatment, and breakthrough pain (flare-ups of intense pain despite round-the-clock narcotic treatment). Fentanyl is an extremely powerful analgesic, 50–100-times more potent than morphine. Fentanyl harbors massive risk for addiction and abuse regardless of its prescription form. Fentanyl abuse is especially dangerous to those without a tolerance to opioids. The substance’s already elevated risk of overdose is multiplied when someone without a tolerance abuses it.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.15 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DURAGESIC-100

Approved Use

Fentanyl transdermal system is a transdermal formulation of fentanyl indicated for the management of persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is required for an extended period of time, and the patient cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer. Fentanyl transdermal system contains fentanyl, a full opioid agonist. Fentanyl transdermal system is indicated for the management of persistent, moderate to severe chronic pain in opioid‑tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. (1) Fentanyl transdermal system is NOT intended for use as an as-needed analgesic. (1)

Launch Date

6.4998723E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.91 ng/mL
100 μg single, intravenous
dose: 100 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.61 ng/mL
400 μg single, oral transmucosal
dose: 400 μg
route of administration: Oral transmucosal
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.81 ng/mL
400 μg single, sublingual
dose: 400 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.76 ng × h/mL
100 μg single, intravenous
dose: 100 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.18 ng × h/mL
400 μg single, oral transmucosal
dose: 400 μg
route of administration: Oral transmucosal
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.76 ng × h/mL
400 μg single, sublingual
dose: 400 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
100 μg single, intravenous
dose: 100 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.9 h
400 μg single, oral transmucosal
dose: 400 μg
route of administration: Oral transmucosal
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10 h
400 μg single, sublingual
dose: 400 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
FENTANYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Disc. AE: Apnea, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Apnea
Respiratory depression
Bradypnea
Tachycardia
Diaphoresis
Sources: Page: p.463
150 ug 1 times / hour multiple, transdermal
Overdose
Dose: 150 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 150 ug, 1 times / hour
Sources:
unknown, 31
n = 1
Health Status: unknown
Age Group: 31
Sex: M
Population Size: 1
Sources:
Disc. AE: Respiratory arrest...
AEs leading to
discontinuation/dose reduction:
Respiratory arrest (grade 5)
Sources:
225 ug 1 times / hour multiple, transdermal
Overdose
Dose: 225 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 225 ug, 1 times / hour
Sources: Page: p.51
unhealthy, 32
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 32
Sex: F
Population Size: 1
Sources: Page: p.51
Disc. AE: Syncope, Acute coronary syndrome...
AEs leading to
discontinuation/dose reduction:
Syncope
Acute coronary syndrome
Sources: Page: p.51
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 14
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 14
Other AEs: Hypoxia, Nausea...
Other AEs:
Hypoxia (50%)
Nausea (75%)
Sources: Page: p.13, 14
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 15
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 15
Other AEs: Somnolence...
Other AEs:
Somnolence (87.5%)
Sources: Page: p.13, 15
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 16
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 16
Other AEs: Vomiting...
Other AEs:
Vomiting (50%)
Sources: Page: p.13, 16
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Disc. AE: Somnolence, Dizziness...
AEs leading to
discontinuation/dose reduction:
Somnolence (3%)
Dizziness (3%)
Hallucinations (1.5%)
Dry mouth (1.5%)
Headache (1.5%)
Nausea (1.5%)
Vomiting (1.5%)
Sources: Page: p.309
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Disc. AE: Confusion, Restlessness...
AEs leading to
discontinuation/dose reduction:
Confusion (acute)
Restlessness (mild)
Visual hallucinations
Sweating
Miosis
Sources: Page: p.199
200 ug 6 times / day multiple, sublingual
Recommended
Dose: 200 ug, 6 times / day
Route: sublingual
Route: multiple
Dose: 200 ug, 6 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Disc. AE: Respiratory depression, Opioid abuse...
AEs leading to
discontinuation/dose reduction:
Respiratory depression (grade 4)
Opioid abuse
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Apnea Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Bradypnea Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Diaphoresis Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Respiratory depression Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Tachycardia Disc. AE
6 mg single, transdermal (total)
Overdose
Dose: 6 mg
Route: transdermal
Route: single
Dose: 6 mg
Sources: Page: p.463
healthy, 15
n = 1
Health Status: healthy
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.463
Respiratory arrest grade 5
Disc. AE
150 ug 1 times / hour multiple, transdermal
Overdose
Dose: 150 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 150 ug, 1 times / hour
Sources:
unknown, 31
n = 1
Health Status: unknown
Age Group: 31
Sex: M
Population Size: 1
Sources:
Acute coronary syndrome Disc. AE
225 ug 1 times / hour multiple, transdermal
Overdose
Dose: 225 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 225 ug, 1 times / hour
Sources: Page: p.51
unhealthy, 32
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 32
Sex: F
Population Size: 1
Sources: Page: p.51
Syncope Disc. AE
225 ug 1 times / hour multiple, transdermal
Overdose
Dose: 225 ug, 1 times / hour
Route: transdermal
Route: multiple
Dose: 225 ug, 1 times / hour
Sources: Page: p.51
unhealthy, 32
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 32
Sex: F
Population Size: 1
Sources: Page: p.51
Hypoxia 50%
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 14
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 14
Nausea 75%
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 14
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 14
Somnolence 87.5%
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 15
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 15
Vomiting 50%
800 ug single, sublingual
Higher than recommended
Dose: 800 ug
Route: sublingual
Route: single
Dose: 800 ug
Sources: Page: p.13, 16
healthy, 33.4
n = 8
Health Status: healthy
Age Group: 33.4
Sex: M+F
Population Size: 8
Sources: Page: p.13, 16
Dry mouth 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Hallucinations 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Headache 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Nausea 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Vomiting 1.5%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Dizziness 3%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Somnolence 3%
Disc. AE
1600 ug 1 times / 15 min multiple, sublingual (max)
Highest studied dose
Dose: 1600 ug, 1 times / 15 min
Route: sublingual
Route: multiple
Dose: 1600 ug, 1 times / 15 min
Sources: Page: p.309
unhealthy, 53±12
n = 65
Health Status: unhealthy
Condition: Pain
Age Group: 53±12
Sex: M+F
Population Size: 65
Sources: Page: p.309
Miosis Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Sweating Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Visual hallucinations Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Confusion acute
Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Restlessness mild
Disc. AE
5 mg single, intravenous
Accidental dose
Dose: 5 mg
Route: intravenous
Route: single
Dose: 5 mg
Sources: Page: p.199
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Pain
Age Group: 62
Sex: M
Population Size: 1
Sources: Page: p.199
Opioid abuse Disc. AE
200 ug 6 times / day multiple, sublingual
Recommended
Dose: 200 ug, 6 times / day
Route: sublingual
Route: multiple
Dose: 200 ug, 6 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
Respiratory depression grade 4
Disc. AE
200 ug 6 times / day multiple, sublingual
Recommended
Dose: 200 ug, 6 times / day
Route: sublingual
Route: multiple
Dose: 200 ug, 6 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Pain
Sources: Page: p.1
OverviewDrug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
likely
major
yes (co-administration study)
Comment: Rate: 61 pmol/min/mg protein; Activity (Fentanyl): 1.03 nmol/min/nmol CYP (Biochem Pharmacol, 53, 1613 (1997)); Coadministartion of Ritonavir (strong CYP3A inhibitor, PO) increased Fentanyl (IV) AUCinf by 2.74-fold.
Page: (Pharm) 17, 28, (PMDA) 17
minor
minor
minor
minor
no
no
no
yes
yes
yes
yes
yes
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Spasm and operative cholangiography.
1975 Jan
Seizure and electroencephalographic changes in the newborn period induced by opiates and corrected by naloxone infusion.
1999 Mar
Continuous paravertebral extrapleural infusion for post-thoracotomy pain management.
1999 Oct
Intraoperative high dose fentanyl induces postoperative fentanyl tolerance.
1999 Sep
Three cases with different presentation of fentanyl-induced muscle rigidity--a rare problem in intensive care of neonates.
2000
Phenytoin, midazolam, and naloxone protect against fentanyl-induced brain damage in rats.
2000 Dec
Low-dose clonidine and neostigmine prolong the duration of intrathecal bupivacaine-fentanyl for labor analgesia.
2000 Feb
Minidose bupivacaine-fentanyl spinal anesthesia for surgical repair of hip fracture in the aged.
2000 Jan
Anaesthetic agents inhibit gastrin-stimulated but not basal histamine release from rat stomach ECL cells.
2000 Jun
An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study.
2000 Oct
Computerised advice on drug dosage to improve prescribing practice.
2001
A highly automated 96-well solid phase extraction and liquid chromatography/tandem mass spectrometry method for the determination of fentanyl in human plasma.
2001
Abuse of topical analgesic.
2001 Apr
A comparison of ropivacaine with fentanyl to bupivacaine with fentanyl for postoperative patient-controlled epidural analgesia.
2001 Apr
The effects of opioids on isolated human pregnant uterine muscles.
2001 Apr
Stress response in infants undergoing cardiac surgery: a randomized study of fentanyl bolus, fentanyl infusion, and fentanyl-midazolam infusion.
2001 Apr
[Prevention of postoperative nausea and vomiting in gynecologic surgery with 3 fixed doses of metoclopramide, droperidol or placebo].
2001 Feb
[Computer simulation and pharmacoeconomics. Computer simulation as an aid for the analysis of operating room efficiency: an example].
2001 Feb
A randomized prospective comparative study of general versus epidural anesthesia for transcervical hysteroscopic endometrial resection.
2001 Feb
MRCP in the evaluation of pancreaticobiliary disease in children.
2001 Feb
Monitoring of end-tidal carbon dioxide partial pressure changes during infrarenal aortic cross-clamping: a non-invasive method to predict unclamping hypotension.
2001 Feb
Pre-emptive efficacy of epidural fentanyl in elective abdominal surgery.
2001 Jan
Interscalene brachial plexus anaesthesia with small volumes of ropivacaine 0.75%: effects of the injection technique on the onset time of nerve blockade.
2001 Jan
[Anesthesia for a patient with cardiac sarcoidosis].
2001 Jan
Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.
2001 Jan
Digitally assisted acromioplasty: the effect of interscalene block on this new surgical technique.
2001 Jan
The Combitube in elective surgery: a report of 200 cases.
2001 Jan
Dexamethasone facilitates discharge after outpatient anorectal surgery.
2001 Jan
A randomized, double-blinded comparison of intrathecal morphine, sufentanil and their combination versus IV morphine patient-controlled analgesia for postthoracotomy pain.
2001 Jan
Distressing upper extremity phantom limb sensation during intravenous regional anesthesia.
2001 Jan-Feb
Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit.
2001 Mar
A dual epidural catheter technique to provide analgesia following posterior spinal fusion for scoliosis in children and adolescents.
2001 Mar
Anaesthetic technique for transoesophageal echocardiography in children.
2001 Mar
Patents

Sample Use Guides

Dosage should be individualized. Some of the factors to be considered in determining the dose are age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used and the surgical procedure involved. Dosage should be reduced in elderly or debilitated patients (see PRECAUTIONS). Vital signs should be monitored routinely. I. Premedication — Premedication (to be appropriately modified in the elderly, debilitated and those who have received other depressant drugs) — 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly 30 to 60 minutes prior to surgery. II. Adjunct to General Anesthesia — See Dosage Range Chart III. Adjunct to Regional Anesthesia - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly or slowly intravenously, over one to two minutes, when additional analgesia is required. IV. Postoperatively (recovery room) - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly for the control of pain, tachypnea and emergence delirium. The dose may be repeated in one to two hours as needed
Route of Administration: Other
0.5 - 5 ng/ml fentanyl inhibited viability of SW1990 cells in vitro.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:56:50 UTC 2021
Edited
by admin
on Fri Jun 25 20:56:50 UTC 2021
Record UNII
UF599785JZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENTANYL
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN   INN  
Official Name English
DURAGESIC
Brand Name English
N-(1-PHENETHYLPIPERIDIN-4-YL)-N-PHENYLPROPIONAMIDE
Systematic Name English
FENTANYL [HSDB]
Common Name English
N02AB03
Code English
FENTANYL CII
USP-RS  
Common Name English
FENTANYL [JAN]
Common Name English
FENTANYL [EP]
Common Name English
MATRIFEN
Common Name English
FENTANYL [MI]
Common Name English
PHENTANYL
Common Name English
FENTANYL [EMA EPAR]
Common Name English
FENTANYL [WHO-DD]
Common Name English
FENTANYL [MART.]
Common Name English
RECUVYRA
Brand Name English
FENTANYL [USAN]
Common Name English
FENTANYL [GREEN BOOK]
Common Name English
AD 923
Code English
FENTANYL [ORANGE BOOK]
Common Name English
FENTANYL [VANDF]
Common Name English
PECFENT
Brand Name English
ABSTRAL-
Common Name English
EN3267
Common Name English
FENTANYL [EP MONOGRAPH]
Common Name English
AD-923
Code English
IDS-NF-001
Code English
FENDROP
Common Name English
R 4263
Code English
EN-3267
Code English
FENTANYL [USP MONOGRAPH]
Common Name English
DUROGESIC D-TRANS
Common Name English
FENTANYL [INN]
Common Name English
FENTANYL CII [USP-RS]
Common Name English
SUBLIMASE
Common Name English
FENTANYL [EMA EPAR VETERINARY]
Common Name English
FENTANEST
Common Name English
PROPANAMIDE, N-PHENYL-N-(1-(2-PHENYLETHYL)-4-PIPERIDINYL)
Common Name English
Classification Tree Code System Code
WHO-VATC QN01AH51
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
NCI_THESAURUS C67413
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
NDF-RT N0000175684
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
LIVERTOX 405
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
CFR 21 CFR 524.916
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
WHO-VATC QN02AB03
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
WHO-ATC N01AH01
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
WHO-VATC QN02AB53
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
NDF-RT N0000175690
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
WHO-ATC N01AH51
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
WHO-ATC N02AB03
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
WHO-VATC QN02AB73
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
WHO-VATC QN01AH01
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
EMA ASSESSMENT REPORTS EFFENTORA (AUTHORIZED: PAIN)
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
DEA NO. 9801
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
EMA ASSESSMENT REPORTS PECFENT (AUTHORIZED: PAIN)
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
NCI_THESAURUS C1506
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
Code System Code Type Description
PUBCHEM
3345
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
ChEMBL
CHEMBL596
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
EPA CompTox
437-38-7
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
RXCUI
4337
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY RxNorm
MESH
D005283
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
HSDB
3329
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
FDA UNII
UF599785JZ
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
EVMPD
SUB07597MIG
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
LACTMED
Fentanyl
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
IUPHAR
1626
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
ECHA (EC/EINECS)
207-113-6
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
DRUG BANK
DB00813
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
INN
1608
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
USP_CATALOG
1269902
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY USP-RS
CAS
437-38-7
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
EMA VETERINARY ASSESSMENT REPORTS
RECUVYRA [AUTHORIZED]
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY DOGS
MERCK INDEX
M5298
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1164
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
NCI_THESAURUS
C494
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
WIKIPEDIA
FENTANYL
Created by admin on Fri Jun 25 20:56:50 UTC 2021 , Edited by admin on Fri Jun 25 20:56:50 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> DERIVATIVE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
DERIVATIVE -> PARENT
CUMULATIVE EXCRETION
URINE
TARGET -> AGONIST
HUMAN RECEPTOR
AGONIST
Ki
TRANSPORTER -> SUBSTRATE
DERIVATIVE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
AGONIST
EC50
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BINDER->LIGAND
BINDING
PARENT -> DERIVATIVE
SALT/SOLVATE -> PARENT
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
CUMULATIVE EXCRETION
FECAL
EXCRETED UNCHANGED
FECAL; URINE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Relative Response Factor - 0.67
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Relative Response Factor - 0.97
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Relative Response Factor - 0.82
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Relative Response Factor - 0.67
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Relative Response Factor - 1.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Relative Response Factor - 0.75
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Relative Response Factor - 0.55
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
ED50(mg/kg) = 0.0061, LD50(mg/kg) = 62, Potency ratio to morphine = 54.1, Potency ratio to fentanyl = 1
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC